Novus Biologicals Inc was acquired by Bio-Techne in July 2014. Novus maintains portfolios of both outsourced and in-house developed antibodies and other reagents among its offerings of more than 250,000 products, delivered via its own digital commerce platform. Novus supplies monoclonal and polyclonal antibodies, recombinant protein and cDNAs for the scientific research community that are of high quality and applicability to current research trends and needs